Non Invasive Biomarkers for Diagnosing Clinically Significant Prostate Cancer

用于诊断具有临床意义的前列腺癌的非侵入性生物标志物

• 批准号: 9187005
• 负责人: PETER S NELSON
• 金额: $ 35.16万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9187005
• 关键词: Adoption; Adverse effects; Advisory Committees; Aggressive behavior; Behavior; Biological Assay; Biological Markers; Biopsy; Characteristics; Clinical; Clinical Data; DNA; Dancing; Detection; Development; Diagnosis; Disease; Disease Progression; Early treatment; Exhibits; Gleason Grade for Prostate Cancer; Growth; Histologic; Indolent; Knowledge; Left; Localized Disease; Longitudinal cohort; Malignant Neoplasms; Malignant neoplasm of prostate; Measurement; Messenger RNA; Molecular; Monitor; Morbidity - disease rate; Natural History; Newly Diagnosed; Operative Surgical Procedures; Pathologic; Patients; Pattern; Physicians; Population Control; Preventive service; Prostate; Prostate-Specific Antigen; Publications; Radiation; Radical Prostatectomy; Recommendation; Risk; Risk Estimate; Sampling; Screening for Prostate Cancer; Specificity; TMPRSS2 gene; Testing; Time; Tissues; Transcript; Tumor Volume; United States; Untranslated RNA; Urine; base; biomarker evaluation; biomarker panel; cancer type; clinical Diagnosis; clinical development; clinically significant; cohort; cost; curative treatments; design; disorder risk; follow-up; health related quality of life; men; migration; mortality; novel; prostate biopsy; public health relevance; randomized trial; screening; tool; treatment strategy; tumor

DESCRIPTION (provided by applicant): Despite the indolent natural history of many newly diagnosed prostate cancers (PC), most men still undergo primary curative therapy with associated side effects and costs, i.e. overtreatment. There is an clear need for the development and implementation of new management strategies for localized PC which would be enhanced if founded upon accurate assessments of disease status and the potential for indolent versus aggressive behavior. This proposal will test the hypothesis that biomarkers indicative of adverse PC characteristics (e.g. high Gleason pattern) can be reproducibly detected in the urine of men with PC. We further hypothesize that initial sampling of a panel of noninvasive urine biomarkers and the repeated evaluation of these markers over time will associate with the presence of significant versus insignificant cancer in the prostate, and thus can be used in informing decisions for surveillance or proceeding with definitive treatment. These hypotheses will be tested through specific aims designed to exploit distinct prostate cancer-associated RNAs using quantitative urine assays and a multi-institutional longitudinal cohort of men managed by active surveillance with attendant biospecimens, pathological, and clinical data. The successful completion of these aims will provide non-invasive tools for the initial and longitudinal assessment of prostate cancers in order to inform accurate treatment decisions for localized disease.

描述（由申请人提供）：尽管许多新诊断的前列腺癌（PC）具有惰性自然病史，但大多数男性仍然接受初级治疗，并伴有相关的副作用和费用，即过度治疗。显然需要为局部 PC 制定和实施新的管理策略，如果建立在对疾病状态以及惰性行为与攻击性行为的潜力的准确评估的基础上，该策略将会得到加强。该提案将检验以下假设：可以在患有 PC 的男性尿液中重复检测到指示不良 PC 特征（例如高格里森模式）的生物标志物。我们进一步假设，一组非侵入性尿液生物标志物的初始采样以及随着时间的推移对这些标志物的重复评估将与前列腺中显着与不显着癌症的存在相关，因此可用于为监测或进行明确的决策提供信息。治疗。这些假设将通过特定目标进行测试，这些目标旨在利用定量尿液分析和多机构纵向男性队列来开发不同的前列腺癌相关 RNA，并通过附带的生物样本、病理学和临床数据进行主动监测。 这些目标的成功完成将为前列腺癌的初始和纵向评估提供非侵入性工具，以便为局部疾病的准确治疗决策提供信息。